.Attribute Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint asks for incorporation of patients along with MASLD and size of liver results in cardio-- kidney-- metabolic trials, when data propose mechanistically plausible perks and also medical safety and security-- and lays out considerations for trial design and also regulatory approval.